Lestaurtinib

Drugbox
IUPAC_name =

---

CAS_number =
CAS_supplemental =
ATC_prefix =
ATC_suffix =
ATC_supplemental =
PubChem = 126565
DrugBank =
chemical_formula =
C=26 | H=21 | N=3 | O=4
molecular_weight = 439.462 g/mol
bioavailability =
protein_bound =
metabolism =
elimination_half-life =
excretion =
pregnancy_AU =
pregnancy_US =
pregnancy_category=
legal_AU =
legal_CA =
legal_UK =
legal_US =
legal_status =
routes_of_administration =

Lestaurtinib (rINN, codenamed CEP-701) is a tyrosine kinase inhibitor undergoing research for the treatment of acute myelogenous leukemia (AML) and myeloproliferative disorders. It is an analog of staurosporine.

As of 2008, it is currently in Phase III clinical trials for AML and Phase II clinical trials for myeloproliferative disorders. [ [http://www.cephalon.com/cephalon_science/pipeline.aspx Cephalon - Pipeline ] ]

It is being developed by Cephalon.

References